Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25729274 | 1.00 | KMT2A (0.49) | KMT2AMEN1GLP1RUSP2TSHR | |
| SCHEMBL25924814 | 0.89 | MEN1 (0.46) | KMT2AMEN1GLP1RTSHRHRH4 | |
| SCHEMBL23879752 | 0.89 | KMT2A (0.49) | KMT2AMEN1GLP1RUSP2TSHR | |
| SCHEMBL26400441 | 0.87 | MEN1 (0.42) | KMT2AMEN1GLP1RUSP2TSHR | |
| SCHEMBL22837784 | 0.87 | KMT2A (0.53) | KMT2AMEN1GLP1RCYP2D6CYP2C19 | |
| SCHEMBL21105906 | 0.87 | KMT2A (0.53) | KMT2AMEN1GLP1RCYP2D6CYP2C19 | |
| SCHEMBL22856471 | 0.85 | KMT2A (0.54) | KMT2AMEN1GLP1RUSP2TSHR | |
| SCHEMBL21105905 | 0.85 | KMT2A (0.54) | KMT2AMEN1GLP1RUSP2TSHR | |
| SCHEMBL25122775 | 0.84 | KMT2A (0.53) | KMT2AMEN1GLP1RTSHRCYP2D6 | |
| SCHEMBL22856474 | 0.84 | KMT2A (0.53) | KMT2AMEN1GLP1RTSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885GLP1R 2955/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KMT2A 1193/4885MEN1 2268/4885GLP1R 4278/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.